REVEAL pivotal
57 evidence topics · 19 sources
Objective
Registered objectives of NCT05606614
Role of the pivotal trial in the development plan
Location and study date
Country of the pivotal trial
Registered sites for NCT05606614 (Parts A and B combined)
| Site | Registry record |
|---|---|
| Duarte, California, United States | “City of Hope” |
| La Jolla, California, United States | “UC San Diego” |
| Oakland, California, United States | “UC San Francisco Benioff Children's Hospital” |
| Chicago, Illinois, United States | “Rush University Medical Center” |
| Baltimore, Maryland, United States | “Kennedy Krieger Institute” |
| Boston, Massachusetts, United States | “Boston Children's Hospital” |
| St Louis, Missouri, United States | “Washington University, St. Louis” |
| Dallas, Texas, United States | “UT Southwestern Children's Medical Center” |
| Montreal, Quebec, Canada | “CHU St. Justine” |
Study design
Single-arm, open-label design with participants as their own control
Registry design: phase 1/2/3 record with outcome assessor masking
FDA written alignment on key design elements
Finalized protocol and statistical analysis plan with a 6-month interim analysis
Natural history external reference: Rett Syndrome Natural History Study
Natural history external reference: trial-aligned analysis cohort and simulated control cohorts
FDA draft guidance on single-arm trials using participants as their own control
Blinded central rating of pre- and post-treatment videos
Eligibility criteria
Registered inclusion and exclusion criteria
Developmental plateau population aged 6 years and older
Rationale for the minimum age of 6 years
Milestone-level eligibility at screening and baseline
Treatment
Registered intervention and arm
Single lumbar intrathecal administration of the high dose
Study outcomes
Rationale for using Rett syndrome developmental milestone assessment response as the primary endpoint
Registered primary outcome of Part B
Primary endpoint definition and key secondary endpoints
The 28 developmental milestones
Selection of the 28 milestones from the natural history study
Natural history: developmental plateau after 6 years of age in the Taysha-funded analysis
Natural history: skill gain, loss, and regain in 1228 females with classic Rett syndrome
“The occurrence and time of gain, loss, and regain of 51 developmental skills was collected during in-person visits in the RTT Natural History Study from 1228 females with Classic RTT and a pathogenic loss-of-function variant in MECP2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Regain of lost skills was infrequent for most skills, occurred mainly before 6 years old, and within 2 years of loss. After 6 years old, the incidence of either gaining or regaining skills was low.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lack of gain or regain of skills beyond 6 years old suggest that any functional gains in these skills after a clinical intervention would represent an important indicator of efficacy as a clinical trial endpoint in RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this restricted set of developmental skills, the percentage of participants who gained at least one of these 38 skills fell below 5% per year after 6 years of life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: advantages of developmental endpoints in trials that cannot be double-blind
“This is especially critical for clinical trials that preclude conducting studies in a double-blind fashion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The advantages of these developmental endpoints are: (1) they are easily defined, (2) binary, and (3) likely to be emergent with an effective treatment paradigm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“trials to define the expected trajectory and likelihood of gain or regain in an untreated cohort as a comparator to participants in an open label trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: earlier analysis of developmental skills
“Early developmental skills were acquired by many, but clear differences from normal emerged, particularly in skills expected after age 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data may serve for planning and interpretation of early intervention studies in RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychometric validation of the RS-DMA in the RESUME study
RS-DMA milestone with lower rater agreement: identifies body parts
RS-DMA historical caregiver interview compared with performative assessment
Limitations of existing Rett syndrome outcome assessments for single-arm designs
FDA interactions on the responder definition and the assessment
Caregiver views on meaningful milestone gains
Key secondary endpoint instrument: Revised Motor Behavior Assessment
“Using data from a natural history study (n = 1,075), we examined the factor structure, internal consistency, and validity of the clinician-reported Motor Behavior Assessment scale (MBA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The analysis resulted in a five-factor model: (1) motor dysfunction, (2) functional skills, (3) social skills, (4) aberrant behavior, and (5) respiratory behaviors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further work is needed to evaluate this measure longitudinally and to add items related to the RTT phenotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary endpoint instrument: Clinical Global Impression scales with Rett-specific anchors
“Despite its favorable assay sensitivity in clinical trials, as a global measure, the Clinical Global Impression Scale is not specific to the signs and symptoms of the disorder under study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Development of key anchors for the scale, specific to the disorder being assessed, holds promise for enhancing the validity and reliability of the measure for disorders such as Rett syndrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Validation status of Rett syndrome outcome measures
“Reliability, validity, and responsiveness profiles were mostly incomplete; there were limited content validation data, particularly parent-informed relevance, comprehensiveness and comprehensibility of items; and no data on meaningful change or cross-cultural validity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Validity data are not available although evidence of responsiveness was suggested in the paediatric Phase 2 [39] and 3 [14] trofinetide trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size and power
Overenrollment to 17 participants
Description of analysis sets
Null hypothesis and success threshold
Derivation of the 6.7% null threshold
Plateau-anchored, baseline-adjusted aggregate responder analysis
Primary analysis, interim analysis, and rater allocation by time point
Results
Participant disposition
Acute post-dosing safety monitoring period completed
Baseline characteristics
Age distribution of dosed participants
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-related serious adverse event: peripheral sensory neuropathy
Pooled safety across the REVEAL Phase 1/2, REVEAL pivotal, and ASPIRE trials: November 2026 cutoff
Study limitations
Summary
- Design and comparator: REVEAL Pivotal is a single-arm, open-label trial with no concurrent control. Efficacy is judged against an external null response rate of 6.7% (1 of 15 participants) derived from the Rett Syndrome Natural History Study, with a 33% response rate (5 of 15) as the minimum threshold for success. The natural history analysis cites sham lumbar puncture, functional unblinding from required immunosuppression, and delayed treatment as ethical and methodological obstacles to a controlled design.
- Derivation of the null: the 28 milestones, the minimum age of 6 years, the time-since-loss rules, and the 6.7% threshold come from analyses of Rett Syndrome Natural History Study data. The highest spontaneous gain rate observed after 6 years of age was 3%, corresponding to 0.45 expected spontaneous responders among 15 participants, and one spontaneous responder (6.7%) was selected as the null threshold because the responder count must be discrete.
- Baseline and milestone eligibility: a milestone is eligible for gain or regain when medical history confirms that it was never achieved or was lost sufficiently long ago and an in-clinic video assessment confirms that it is not demonstrated. In the RESUME validation study, agreement between the RS-DMA historical caregiver interview and the performative RS-DMA averaged 81.8%, with more than one-third of items at slight or fair agreement.
- Endpoint validation: the RS-DMA was validated in a non-interventional study of 13 participants. Inter-rater agreement was substantial to excellent for 27 of the 28 milestones and fair for identifying body parts, and 83% of video recordings were rated feasible for central rating. A responder is a participant who gains or regains at least 1 of 28 milestones, so a single milestone of any type meets the definition.
- Blinding and assessment: only central raters are masked, and only to the timing of each video. Milestone demonstration is a performed task administered in clinic. The 2025 FDA draft guidance states that self-controlled studies can be particularly persuasive when a condition is universally degenerative in all affected individuals and the intervention is expected to lead to improvement, and that objectively measured endpoints that are not effort-dependent are critical to interpreting self-controlled or other non-blinded trials. The natural history data describe a developmental plateau from 6 years of age and slow loss of gross motor skills during Stage III.
- Secondary endpoints: the key secondary measures are the R-MBA and CGI-I. One publication describes the reliability, validity, and responsiveness profiles of the outcome measures it assessed as mostly incomplete, with no data on meaningful change, and the psychometric study of the clinician-reported MBA called for longitudinal evaluation of the measure.
- Size, timing, and analysis: 17 females aged 6 to under 22 years were dosed against a planned 15. A BLA may rest on a 6-month interim analysis, while the registered primary outcome runs from baseline through week 52 and the statistical analysis plan names a 12-month primary analysis. The registered primary outcome is worded as a change from baseline in the percentage of responders, which differs from the response rate the sponsor describes. No published protocol or statistical analysis plan was identified.
- Population and extrapolation: eligibility is limited to females with classic Rett syndrome and a loss-of-function MECP2 variant, excluding atypical Rett syndrome and participants needing invasive ventilation. The sponsor plans to extrapolate efficacy to children aged 2 to under 6 years, an age range in which the natural history analysis reports spontaneous first-time gain of a single milestone as high as 97%.
- Results and safety reporting: no efficacy results have been reported; topline interim data are expected in the first half of 2027. Safety has been reported in company filings and press releases, mostly pooled with the phase 1/2 and ASPIRE trials (33 participants). One pivotal participant had a treatment-related Grade 2 serious adverse event of peripheral sensory neuropathy about 6 weeks after dosing in July 2026; no adverse event table specific to the pivotal trial was identified.
- Reporting consistency: the third quarter 2026 Form 10-Q states that the pivotal trial is taking place in the United States, while the combined registry record lists a site in Montreal and the sponsor reported a No Objection Letter from Health Canada before site activation.